Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention
Drugs and Drug Candidates · 2022
DOI: 10.3390/ddc1010003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, 2022. Verfasst von François Marceau. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
The hope for the rapid discovery of an effective drug therapy for COVID-19 has led to several efforts to repurpose drugs approved for other indications. Lysosomotropic drugs, organic amines such as chloroquine, hydroxychloroquine, amiodarone and many others, were found to interfere with the viral life cycle in vitro but have failed in clinical trials. The properties of lysosomotropic drugs and the vacuolar cytopathology induced by them are briefly reviewed, including the critical role of lipophilicity, the central role of vacuolar (V)-ATPase for their concentration in acidic organelles, the altered function of these organelles including impaired endocytosis and secretion, macroautophagic accumulation and secondary phospholipidosis. The apparent preferential uptake of lysosomotropic drugs by phagocytic leukocytes (macrophages, neutrophils) and the high concentrations needed for a sustained disruption of vacuolar trafficking may have contributed to the failure of lysosomotropic drug repurposing for COVID-19.
Förderung
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Marceau, F. (2022). Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention. Drugs and Drug Candidates. https://doi.org/10.3390/ddc1010003
Vancouver
Marceau F. Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention. Drugs and Drug Candidates. 2022. doi:10.3390/ddc1010003
BibTeX
@article{Marceau2022,
author = {Marceau, François},
title = {Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention},
journal = {Drugs and Drug Candidates},
year = {2022},
doi = {10.3390/ddc1010003}
}
EUVIMED